Primary Tumour Type, Clinical Features, Treatment and Outcome of Patients with Iris Metastasis. (17th November 2022)

• Record Type: Journal Article
• Authors: Liu, Tao; Bai, Feng; Yang, Li; Liu, Li; Xiao, Jun; Liu, Xiaoli
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 7/8(2022)
• Page Start: 1726
• Page End: 1732
• Publication Date: 2022-11-17
• Subjects: Iris metastasis -- uveal metastasis -- lung carcinoma -- breast carcinoma -- elevated intraocular pressure; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1939392
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To describe the primary tumour type, clinical features, treatment and outcome of patients with Iris metastasis. Methods: Retrospectively analyzed articles published from 1934 to 2019 in the PubMed database. Results: In total, 133 eyes of 125 patients with iris metastatic carcinoma were retrieved. The average age at metastasis diagnosis of the patients was 56 ± 15 years; 60 left eyes and 49 right eyes were involved. The most common primary tumors were lung carcinoma (42%) and breast carcinoma (15%). Approximately one-third of the patients were first diagnosed in the ophthalmology department before the primary tumor was detected. Twenty-two percent of iris metastases were discovered before and 33% were discovered after systemic metastasis. The most common complaints were blurred vision and pain. The clinical features included iris masses, neovascularization and keratic precipitates. 57 patients (64%, N = 90) had an elevated intraocular pressure. Local administration of radiation therapy or intraocular injections of anti-VEGF drugs relieved eye discomfort and controlled the high intraocular pressures. Conclusions: Iris nodules with increased intraocular pressure and neovascularization may indicate iris metastasis. Lung cancer is the most common primary tumor.